In the United States, obesity is a condition that affects as much as nearly 42% of the population and is associated with over $170 billion in medical costs, according to the Centers for Disease Control and Prevention
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication
Pregnant individuals may think more carefully about what they put into their bodies than ever before
4 It is estimated that 2535% of patients with obesity and diabetes also have NASH
The most common side effects of tirzepatide are gastrointestinal: Nausea: Reported by 12-33% of participants depending on dose (most common early in treatment) Diarrhea: 12-21% of participants Constipation: 6-11% of participants Vomiting: 5-13% of participants Decreased appetite: Expected therapeutic effect but can be uncomfortable These side effects are typically most intense during the first few weeks at each new dose level and tend to improve as the body adjusts
NAFLD leads to a 2-3-fold increased risk of DM2 development, 1,2 since liver fat accumulation is a crucial pathogenetic component
